Akeso, a China-based biopharmaceutical company, has announced the establishment of the Akeso Global R&D Centre. It signifies a step in Akeso's innovative globalisation strategy, as it plays a crucial role in driving the company's sustained and high-speed innovative development, enabling the company to enhance its global competitive edge in the field of new drug development.

The Akeso Global R&D Centre project is situated in Shanghai's Zhangjiang headquarters park (Youchuang Park), spanning an area of 14,454.90 m², with a total construction area of 66,568.86 m². The planned investment for the project is estimated to be RMB 850 million.

Leveraging Akeso's internationally advanced drug innovation and development system, the Akeso Global R&D Centre will align with the group's R&D strategy and proactively track/lead the latest global research trends. It will focus on cutting-edge areas like gene therapy, cell therapy, neurological diseases, and anti-aging, establishing a leading pipeline for ongoing research while establishing platforms and teams dedicated to tumor microenvironment big data analysis and translational research.

Additionally, the Akeso Global R&D Centre will utilise Zhangjiang as a gateway, leveraging China's strengths to connect with global resources, fostering the development of a world-class biopharmaceutical industry cluster in Zhangjiang while facilitating the global expansion of China's domestic innovative drugs.

The company is actively developing a diverse pipeline of over 30 innovative assets in areas such as cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, 13 Phase III studies ongoing.